Cybin (CLXPF) News Today $9.61 +0.29 (+3.11%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChart All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Cybin gears up for Phase 3 trial in depression treatmentOctober 3, 2024 | uk.investing.comCYBN Stock Earnings: Cybin Beats EPS for Q1 2024August 9, 2024 | investorplace.comCYBN Stock Earnings: Cybin Beats EPS for Q4 2023June 27, 2024 | investorplace.comCybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programsSeptember 14, 2023 | finance.yahoo.comPsychedelics Companies Join The Race To Develop Much-Needed Anxiety TreatmentJanuary 16, 2023 | benzinga.comCybin Provides Update on its Intellectual Property Portfolio - Business WireOctober 6, 2022 | businesswire.comCybin, GH Research Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways - BenzingaOctober 4, 2022 | benzinga.comMindset Pharma says licensing agreement with Cybin gives it multiple 'shots for the goal' - Proactive Investors USASeptember 29, 2022 | proactiveinvestors.comCybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds FamilySeptember 27, 2022 | benzinga.comNA Proactive news snapshot: Nevada Copper, Mindset Pharma, EverGen Infrastructure, Psyched Wellness, BetterLife Pharma, Endexx, Group Eleven Resources... - Proactive Investors USASeptember 27, 2022 | proactiveinvestors.comCybin to Participate in Upcoming Scientific and Investor Conferences - Business WireSeptember 21, 2022 | businesswire.comCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks 'Tremendous' Milestone as First Participants Receive Initial CYB003 Dose - StreetInsider.comSeptember 21, 2022 | streetinsider.comCybin Achieves Research and Development Milestones Ahead of Projected Timelines - Business WireSeptember 20, 2022 | businesswire.comFirst Africa Cannabis SPAC to Go Ahead With Cilo Cybin Listing - BloombergSeptember 9, 2022 | bloomberg.comCOMP SERVICES (CMPS), (CSE:OPTI) – Psychedelics May Make People Less Afraid of Death - BenzingaSeptember 7, 2022 | benzinga.com7 Psychedelics Stocks to Buy for a Big Drug Boom - NasdaqSeptember 1, 2022 | nasdaq.comCybin makes positive progress towards its goal of advancing psychedelics to therapeutics - Proactive Investors USASeptember 1, 2022 | proactiveinvestors.com(ALID), ATA (ATAI), (BMNDF), COMP SERVICES (CMPS), Cybin Inc. Common Shares (CYBN), Small Pharma (DMTTF), - BenzingaAugust 31, 2022 | benzinga.comCybin Inc. Common Shares (CYBN) – Cybin Announces Final Adelia Milestone Achievement - BenzingaAugust 31, 2022 | benzinga.comCybin Announces Final Adelia Milestone Achievement - Business WireAugust 31, 2022 | businesswire.comCybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Yahoo FinanceAugust 30, 2022 | finance.yahoo.comWellbeing' CEO Joins Benzinga's Psychedelic Advisory Board - Business WireAugust 30, 2022 | businesswire.comBioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD - StreetInsider.comAugust 30, 2022 | streetinsider.comCybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Business WireAugust 30, 2022 | businesswire.comCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector - StreetInsider.comAugust 26, 2022 | streetinsider.comStifel analysts still bullish on psychedelic stocks, citing attractive risk-reward profile - Proactive Investors USAAugust 24, 2022 | proactiveinvestors.comMDD - Latest News and breaking headlines - BenzingaAugust 17, 2022 | benzinga.comCybin, Clinilabs Says DEA Grants it Schedule 1 License for CYB003 to Treat Major Depressive Disorder - Marketscreener.comAugust 17, 2022 | marketscreener.comPsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders - StreetInsider.comAugust 17, 2022 | streetinsider.com2022-08-17 | NEO:CYBN | Press Release | Cybin Inc. - StockhouseAugust 17, 2022 | stockhouse.comBREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat DepressionAugust 17, 2022 | benzinga.comFilament Health : Q2 MD&A - Marketscreener.comAugust 16, 2022 | marketscreener.comLaunched Pre-COVID, A Psychedelics Company Finds Its Sweet Spot In Being –And Staying- Remote - ForbesAugust 15, 2022 | forbes.comThis Psychedelics Company Is Setting Up An Equity Program For Up To $35M In SharesAugust 9, 2022 | benzinga.comPsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program - StreetInsider.comAugust 4, 2022 | streetinsider.comCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants - StreetInsider.comJuly 28, 2022 | streetinsider.comKetamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders - StreetInsider.comJuly 28, 2022 | streetinsider.comCybin Announces Date of Annual Meeting of Shareholders - Yahoo FinanceJuly 26, 2022 | finance.yahoo.comCybin Announces Date of Annual Meeting of Shareholders - Business WireJuly 25, 2022 | businesswire.comCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study - StreetInsider.comJuly 25, 2022 | streetinsider.comCybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical - Business WireJuly 11, 2022 | businesswire.comCybin gets FDA green light to begin clinical trial of psilocybin candidate for depression - Seeking AlphaJune 27, 2022 | seekingalpha.comCybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder - Business WireJune 27, 2022 | businesswire.comCybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022 - Yahoo FinanceJune 16, 2022 | finance.yahoo.comCybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder - Business WireJune 9, 2022 | businesswire.comCybin Acquires DMT Clinical Study from Entheon Biomedical - Business WireJune 7, 2022 | businesswire.com2022-06-03 | NEO:CYBN | Press Release | Cybin Inc. - StockhouseJune 3, 2022 | stockhouse.comFive Next-Gen Psychedelics Clinical Trials Taking Place in 2022 - StreetInsider.comJune 2, 2022 | streetinsider.comCybin submits application for trial of psilocybin-based CYB003 to treat depression - Seeking AlphaJune 2, 2022 | seekingalpha.comCybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy - Business WireJune 2, 2022 | businesswire.com Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CLXPF and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now CLXPF Media Mentions By Week CLXPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLXPF News Sentiment▼0.000.59▲Average Medical News Sentiment CLXPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLXPF Articles This Week▼00▲CLXPF Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CLXPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GLPG News XNCR News EVO News ARQT News RCUS News EVTCY News NRIX News IMCR News KNSA News OCUL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CLXPF) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
